Provided by Tiger Trade Technology Pte. Ltd.

Editas Medicine

3.11
+0.17005.78%
Post-market: 3.10-0.0100-0.32%19:55 EDT
Volume:2.12M
Turnover:6.63M
Market Cap:475.83M
PE:-4.26
High:3.25
Open:2.98
Low:2.95
Close:2.94
52wk High:4.54
52wk Low:1.66
Shares:153.00M
Float Shares:115.00M
Volume Ratio:0.54
T/O Rate:1.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7307
EPS(LYR):-1.8036
ROE:-118.82%
ROA:-23.29%
PB:4.52
PE(LYR):-1.72

Loading ...

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD), Tempus AI, Inc. Class A (TEM) and Editas Medicine (EDIT)

TIPRANKS
·
May 08

Editas Medicine Is Maintained at Buy by Chardan Capital

Dow Jones
·
May 06

Analyst Phil Nadeau Reiterates Buy on Editas Medicine, Citing Promising EDIT-401 Data, Strong Cash Runway, and Large Untapped HeFH Opportunity

TIPRANKS
·
May 06

Editas Medicine Q1 net loss narrows

Reuters
·
May 05

Editas Medicine Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $2.831M Miss $4.065M Estimate

Benzinga Earnings
·
May 05

BRIEF-Editas Medicine Q1 Net Income USD -24.982 Million Vs. IBES Estimate USD -26.5 Million

Reuters
·
May 05

Editas Medicine Q1 Basic EPS USD -0.26

THOMSON REUTERS
·
May 05

Editas Medicine Q1 Collaboration and Other Research and Development Revenue USD 2.8 Million

THOMSON REUTERS
·
May 05

Editas Medicine Announces First Quarter 2026 Results and Business Updates

GlobeNewswire
·
May 05

Editas Medicine announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 29

Editas Medicine to present preclinical data for EDIT-401 hyperlipidemia therapy at conferences

Reuters
·
Apr 28

Editas publishes corporate presentation on in vivo gene editing, LDL-C lowering candidate EDIT-401

Reuters
·
Apr 17

Editas Medicine replaces Ernst & Young with PwC as auditor for 2026

Reuters
·
Apr 08

JonesTrading Sticks to Their Buy Rating for Editas Medicine (EDIT)

TIPRANKS
·
Apr 07

USPTO Ruling Impacts Editas Medicine CRISPR IP Position

TIPRANKS
·
Mar 27

Editas Medicine Inc - Uspto Reaffirms Ptab Decision Favoring Broad Institute in CRISPR/Cas9 Patent Interference

THOMSON REUTERS
·
Mar 27

Editas Medicine patent interference narrows; USPTO reaffirms PTAB ruling favoring Broad Institute

Reuters
·
Mar 27

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT)

TIPRANKS
·
Mar 17

Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects

TIPRANKS
·
Mar 11

Editas Medicine upgraded to Buy from Hold at JonesResearch

TIPRANKS
·
Mar 10